Phaseline

Targets › MECP2

MECP2 (Methyl-CpG-binding protein 2): drug programs, companies and trials

3 programs from 3 companies in 5 trials: 3 Phase 3, 2 Phase 1; Neurology, Psychiatry; next expected readout Sep 2027.

Chromosomal protein that binds to methylated DNA. It can bind specifically to a single methyl-CpG pair. It is not influenced by sequences flanking the methyl-CpGs. (UniProt, P51608)

Open in Phaseline: the race on MECP2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Taysha Gene TherapiesTSHA-102
recombinant, non-replicating, self-complementary AAV9 vector encoding miniMECP2 gene, deli
MECP2Phase 3Rett SyndromeNov 2028
NeurogeneNGN-401
Recombinant AAV9 carrying full-length human MECP2 transgene
MECP2Phase 3Rett SyndromeDec 2029
Ionis PharmaceuticalsION440
Antisense oligonucleotide targeting MECP2
MECP2Phase 1Methyl CpG Binding Protein 2 (MECP2) Duplication SyndromeSep 2027

Conditions

Rett Syndrome (4) Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (1)

Modalities

other (2), small molecule (1)

Companies

Taysha Gene Therapies (1) Ionis Pharmaceuticals (1) Neurogene (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.